{{Rsnum
|rsid=1989754
|Gene=FGF20
|Chromosome=8
|position=17000966
|Orientation=plus
|GMAF=0.405
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;G)
|geno3=(G;G)
|Gene_s=FGF20
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;G)
| geno3=(G;G)
| CEU | 16.2 | 52.3 | 31.5
| HCB | 24.1 | 46.0 | 29.9
| JPT | 15.9 | 56.6 | 27.4
| YRI | 0.7 | 19.7 | 79.6
| ASW | 7.0 | 33.3 | 59.6
| CHB | 24.1 | 46.0 | 29.9
| CHD | 30.6 | 49.1 | 20.4
| GIH | 24.8 | 44.6 | 30.7
| LWK | 3.6 | 29.1 | 67.3
| MEX | 29.3 | 37.9 | 32.8
| MKK | 7.1 | 45.8 | 47.1
| TSI | 23.5 | 45.1 | 31.4
| HapMapRevision=28
}}

{{omim
|desc=FIBROBLAST GROWTH FACTOR 20; FGF20
|id=605558
|rsnum=1989754
}}

{{PMID|15122513|OA=1
}} Fibroblast growth factor 20 polymorphisms and haplotypes strongly influence risk of Parkinson disease.

{{PMID|15967032|OA=1
}} Lack of evidence for a genetic association between FGF20 and Parkinson's disease in Finnish and Greek patients.

{{PMID|18252210|OA=1
}} Variation in the miRNA-433 binding site of FGF20 confers risk for Parkinson disease by overexpression of alpha-synuclein.

{{PMID|19133659|OA=1
}} FGF20 and Parkinson's disease: no evidence of association or pathogenicity via alpha-synuclein expression.

{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}